Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

vWf inhibitor detection by competitive ELISA

M W Stewart¹, W S Etches, A R Shaw

¹Department of Laboratory Medicine and Pathology, University of Alberta Hospitals, Edmonton, Canada.

Journal of Immunological Methods

|January 15, 1997

Summary

Researchers detected a von Willebrand factor (vWf) inhibitor in patients with bleeding disorders using a novel ELISA. This assay can distinguish acquired von Willebrand disease from congenital forms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Recruitment of Older African Americans in Alzheimer's Disease Clinical Trials Using a Community Education Approach.

The journal of prevention of Alzheimer's disease·2022

Same author

Representation of Racial and Ethnic Minority Populations in Dementia Prevention Trials: A Systematic Review.

The journal of prevention of Alzheimer's disease·2022

Same author

The chameleon rash: a review of the polyphenotypic dermatoses of dermatomyositis.

Clinical and experimental dermatology·2021

Same author

Cutaneous features of dermatomyositis associated with myositis-specific antibodies.

The British journal of dermatology·2016

Same author

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.

Diabetes, obesity & metabolism·2014

Same author

Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage.

Diabetologia·2010

Area of Science:

Hematology
Immunology
Clinical Chemistry

Background:

Von Willebrand factor (vWf) is crucial for platelet adhesion and Factor VIII stability.
Acquired von Willebrand disease (vWD) can arise from autoantibodies against vWf.
Distinguishing acquired vWD from congenital vWD is clinically important.

Purpose of the Study:

To develop and validate a competitive enzyme-linked immunosorbent assay (ELISA) for detecting vWf inhibitors.
To characterize the mechanism of vWf inhibitor-mediated platelet activation.
To assess the utility of the developed ELISA in differentiating acquired vWD from congenital vWD.

Main Methods:

Competitive ELISA using immobilized vWf.
Flow cytometry to detect patient IgG binding to vWf.

Related Experiment Videos

Platelet function assay involving vWf-coated beads and platelet-rich plasma (PRP).

Inhibition studies using monoclonal antibody IV.3.

Main Results:

A vWf inhibitor was detected in plasma from patients with bleeding histories using the competitive ELISA.
Patient IgG antibodies demonstrated binding to immobilized vWf.
The inhibitor potentiated vWf-mediated platelet activation in a manner dependent on Fc receptor engagement.
Addition of mAb IV.3 abolished the potentiation, indicating Fc-dependent enhancement.

Conclusions:

The developed competitive ELISA is effective for quantifying vWf and detecting vWf inhibitors in plasma.
The findings suggest an Fc receptor-mediated mechanism for inhibitor-induced platelet activation.
This ELISA method offers a valuable tool for differentiating acquired vWD from congenital vWD.